Contract Pharma Manufacturing News

  1. uBriGene And Cellinfinity BIO Announce Strategic Partnership To Advance In Vivo CAR-T Therapies 3/30/2026

    uBriGene Biosciences, a leading global CDMO specializing in lentiviral vector manufacturing and Advanced Therapy Medicinal Product (ATMP) development, today announced a strategic partnership with Cellinfinity BIO, a biotechnology company developing in vivoCAR-T therapies targeting hematologic and solid tumors.

  2. Kindeva® Commemorates 70 Years Of The pMDI As Inventors Are Inducted Into The 'National Inventors Hall Of Fame' 3/26/2026
  3. Lifecore Biomedical Signs Two New Agreements With Existing U.S. Biopharmaceutical Customer 3/26/2026

    Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that it has signed two CDMO manufacturing service agreements with an existing U.S. biopharmaceutical customer.

  4. Neion Bio Emerges From Stealth With Multi-Product Biosimilar Partnership Leveraging Its Cutting-Edge Genetic Engineering Platform 3/26/2026

    Neion Bio, a biotechnology company revolutionizing the production of biologic medicines, today announced its emergence from stealth and the signing of its first co-development and supply agreement with a major global pharmaceutical company.

  5. SHINE And C-Ray Therapeutics Establish Strategic Partnership For Exclusive Distribution Of Non-Carrier-Added Lu-177 In Mainland China 3/26/2026

    SHINE Technologies, LLC today announced a supply agreement with C-Ray Therapeutics (Chengdu, China), a global radiopharmaceutical CRDMO, establishing C-Ray as SHINE's exclusive distribution partner for non-carrier-added lutetium-177 (n.c.a. Lu-177) across mainland China, excluding certain pre-existing SHINE partnerships.

  6. Clarity Signs A Large-Scale Manufacturing Supply Agreement For Copper-64 With Theragenics 3/25/2026

    Clarity Pharmaceuticals (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the signing of a large-scale Manufacturing Supply Agreement for copper-64 with Theragenics.

  7. DifGen Pharmaceuticals And Aveva Drug Delivery Systems Lead U.S. Technology Transfer And Platform Development Collaboration For Multi-Indication Immune Restoration Therapy With Active IND Programs And Phase 2b/3 Authorization In PASC 3/25/2026

    DifGen Pharmaceuticals and Aveva Drug Delivery Systems today announced a strategic platform collaboration with Biostax Corp d/b/a Attune Biotech, SGP Holdings, and Callan JMB to lead U.S.-based technology transfer, platform formulation development, manufacturing scale-up, and support future clinical development programs for the JKB-122 upstream immune restoration platform.

  8. Alteogen Enters Into A License Agreement With Biogen For Development And Commercialization Of Hybrozyme™-Based Subcutaneous Biologics 3/25/2026

    Alteogen Inc. (KOSDAQ: 196170) announced today that it has entered into an exclusive license agreement with Biogen Inc. for the development and commercialization of subcutaneous (SC) formulations of biologics utilizing ALT-B4 powered by Alteogen's Hybrozyme™ technology.

  9. Fuji Pharma And Gedeon Richter Conclude Agreement For Joint Development Projects In Women's Health 3/24/2026

    Fuji Pharma Co., Ltd. (Headquarters: Chiyoda‑ku, Tokyo; hereinafter “Fuji Pharma”) announces that, in relation to the strategic collaboration with Gedeon Richter Plc. (Headquarters: Hungary; hereinafter “Richter”) disclosed on February 3, 2026, the two companies have entered into and signed an agreement regarding the joint development of multiple product candidates in the field of women’s health.

  10. Applied StemCell And Cellipont Bioservices Partner To Offer A Seamless Path For iPSC-Derived Cell Therapy Development 3/24/2026

    Applied StemCell, Inc. (“ASC”), a genome engineering company with deep expertise in induced pluripotent stem cell (iPSC) technology and Cellipont Bioservices, a cell therapy contract development and manufacturing organization (CDMO), today announced a strategic collaboration designed to streamline and accelerate the development of iPSC-derived cell therapies.